Phase 3 of the Covaxin trial will begin at PGI Rohtak on November 20. The medical institute will administer two doses of the vaccine to 200 candidates.
Covaxin is being developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research (File photo)
The Post Graduate Institute of Medical Science, Rohtak in Haryana will start phase 3 of Covid-9 vaccine candidate Covaxin from November 20, the vice-chancellor of the institute said on Wednesday.
PGIMS V-C Prof OP Kalra said that, in the third phase, 200 volunteers will be administered two doses of the vaccine to study the antibody responses. “There will be two doses, the second dose will be given 28 days after the first dose,” Prof Kalra said, adding that he expects the vaccine’s efficacy to be more than 90 per cent.
Covaxin is being developed indigenously by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Last month, the vaccine maker had said it had successfully completed an interim analysis of Phase 1 and 2 trials and is initiating Phase 3 trials.
Bharat Biotech had on Monday said the Phase 3 trial of Covaxin will involve 26,000 volunteers across 25 centres in India and is being conducted in partnership with the ICMR.
It is the largest clinical trial conducted for a Covid-19 vaccine in India.
This is India’s first Phase 3 efficacy study for a Covid-19 vaccine, and the largest Phase 3 efficacy trial ever conducted.
Earlier in the day, Haryana Health Minister Anil Vij offered to be the first volunteer to get vaccinated.
“Trial for third phase of Covaxin, a coronavirus vaccine product of Bharat Biotech, to start in Haryana on 20th November. I have offered myself as the first volunteer to get vaccinated,” Vij said in a tweet.